FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Lebwohl

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Skin

Phenomena

Ultraviolet Rays

Co-author Network

Publications

TOP 3
Mark Lebwohl; Craig L Leonardi; Shu Li; Jörg C Prinz; Christopher E M Griffiths; Cynthia Guzzo; Ming-Chun Hsu; Philippe Szapary; Newman Yeilding; Bruce E Strober
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
Mark Lebwohl; Anita Melgaard; Neil Swanson; Zhenyi Xu; Lawrence L Anderson; Brian Berman
Ingenol mebutate gel for actinic keratosis.
Kristian Reich; Philippe O Szapary; Yasmine Wasfi; Newman Yeilding; Kenneth B Gordon; Christopher E M Griffiths; Ming-Chun Hsu; Mark Lebwohl; Elyssa Ott; Kim A Papp
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Lebwohl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Mark Lebwohl; Craig L Leonardi; Shu Li; Jörg C Prinz; Christopher E M Griffiths; Cynthia Guzzo; Ming-Chun Hsu; Philippe Szapary; Newman Yeilding; Bruce E Strober
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
Journal of the American Academy of Dermatology 2012;66(5):731-41.
2012: Mark Lebwohl; Anita Melgaard; Neil Swanson; Zhenyi Xu; Lawrence L Anderson; Brian Berman
Ingenol mebutate gel for actinic keratosis.
The New England journal of medicine 2012;366(11):1010-9.
2012: Kristian Reich; Philippe O Szapary; Yasmine Wasfi; Newman Yeilding; Kenneth B Gordon; Christopher E M Griffiths; Ming-Chun Hsu; Mark Lebwohl; Elyssa Ott; Kim A Papp
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Journal of drugs in dermatology : JDD 2012;11(3):300-12.
2011: Jason J Emer; Amylynne Frankel; Andrew Sohn; Mark Lebwohl
A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis.
Journal of drugs in dermatology : JDD 2011;10(7):735-43.
2011: Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice Gottlieb; John Y M Koo; Neil J Korman; Mark Lebwohl; Craig L Leonardi; Henry W Lim; Alan Menter; Caitriona Ryan; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
Journal of the American Academy of Dermatology 2011;65(1):137-74.
2011: Amylynne Frankel; Andrew Sohn; Rita V Patel; Mark Lebwohl
Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.
Journal of drugs in dermatology : JDD 2011;10(6):666-72.
2011: Ahmed Hadi; Mark Lebwohl
Clinical features of pyoderma gangrenosum and current diagnostic trends.
Journal of the American Academy of Dermatology 2011;64(5):950-4.
2011: Amylynne Frankel; Abby S Van Voorhees; Sylvia Hsu; Neil J Korman; Mark Lebwohl; Bruce F Bebo; Alice Gottlieb
In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?".
Journal of the American Academy of Dermatology 2011;64(4):788-90.
2011: K Reich; Richard G B Langley; Mark Lebwohl; P Szapary; Cynthia Guzzo; Newman Yeilding; S Li; M-C Hsu; C E M Griffiths
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
The British journal of dermatology 2011;164(4):862-72.
2011: Margarita S Lolis; Anna Krishtul; Claudia Vidal; Helen Shim-Chang; Robert Phelps; Mark Lebwohl
Necrolytic migratory erythema associated with a metastatic neuroendocrine tumor.
Cutis; cutaneous medicine for the practitioner 2011;87(2):78-80.
2011: Jason J Emer; Amylynne Frankel; Andrew Sohn; Mark Lebwohl
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis.
The Journal of clinical and aesthetic dermatology 2011;4(2):28-39.
2010: Suhail M Hadi; Hanadi Al-Quran; Ana Paula de Sá Earp; Ahmed S Hadi; Mark Lebwohl
The use of the 308-nm excimer laser for the treatment of psoriasis.
Photomedicine and laser surgery 2010;28(5):693-5.
2010: Mark Lebwohl; Newman Yeilding; Philippe Szapary; Yuhua Wang; Shu Li; Yaowei Zhu; Kristian Reich; Richard G Langley; Kim A Papp
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
Journal of the American Academy of Dermatology 2010;63(4):571-9.
2010: Mark Lebwohl
Tumour necrosis factor-α blockers in the treatment of psoriasis.
The British journal of dermatology 2010;162(6):1169-71.
2010: Annemarie Uliasz; Mark Lebwohl
Evaluation of sensory irritation caused by topical medications using a novel technique.
International journal of dermatology 2010;49(3):269-71.
2010: Jinan Chaarani; Mark Lebwohl
Alefacept: where it stands today.
Expert opinion on drug metabolism & toxicology 2010;6(3):355-61.
2010: Nora Koutruba; Jason Emer; Mark Lebwohl
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis.
Therapeutics and clinical risk management 2010;6():123-41.
2010: Mark Lebwohl; K Papp; C Han; B Schenkel; N Yeilding; Y Wang; Gerald G Krueger
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
The British journal of dermatology 2010;162(1):137-46.
2010: Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.
Journal of the American Academy of Dermatology 2010;62(1):114-35.
2009: Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice B Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
Journal of the American Academy of Dermatology 2009;61(3):451-85.
2009: Mark Lebwohl; Jean-Paul Ortonne; Philippe Andres; Philippe Briantais
Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis.
Cutis; cutaneous medicine for the practitioner 2009;83(4):205-12.
2009: Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
Journal of the American Academy of Dermatology 2009;60(4):643-59.
2009: Mariya Rozenblit; Mark Lebwohl
New biologics for psoriasis and psoriatic arthritis.
Dermatologic therapy 2009;22(1):56-60.
2008: Mark Lebwohl
What is Known About the Association of Antinuclear Antibodies Development During Treatment with TNF Blockers?
The Journal of clinical and aesthetic dermatology 2008;1(3):36-7.
2008: Caroline P Halverstam; Mark Lebwohl
Nonstandard and off-label therapies for psoriasis.
Clinics in dermatology 2008;26(5):546-53.
2008: Annemarie Uliasz; Mark Lebwohl
A new standardized method of evaluating cutaneous irritation from topical medications.
Cutis; cutaneous medicine for the practitioner 2008;82(1):75-7.
2008: Annemarie Uliasz; Joshua Zeichner; Jennifer Soung; Vicky Wong; Mark Lebwohl
A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses.
Cutis; cutaneous medicine for the practitioner 2008;81(6):517-9.
2008: Vaishali Patel; Elizabeth J Horn; Steve J Lobosco; Kathleen M Fox; Seth R Stevens; Mark Lebwohl
Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists.
Journal of the American Academy of Dermatology 2008;58(6):964-9.
2008: Kim A Papp; Richard G B Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet 2008;371(9625):1675-84.
2008: Annemarie Uliasz; Mark Lebwohl
Cutaneous manifestations of cardiovascular diseases.
Clinics in dermatology 2008;26(3):243-54.
2008: Alice Gottlieb; Neil J Korman; Kenneth B Gordon; Steven R Feldman; Mark Lebwohl; John Y M Koo; Abby S Van Voorhees; Craig A Elmets; Craig L Leonardi; Karl R Beutner; Reva Bhushan; Alan Menter
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Journal of the American Academy of Dermatology 2008;58(5):851-64.
2008: Alan Menter; Alice Gottlieb; Steven R Feldman; Abby S Van Voorhees; Craig L Leonardi; Kenneth B Gordon; Mark Lebwohl; John Y M Koo; Craig A Elmets; Neil J Korman; Karl R Beutner; Reva Bhushan
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Journal of the American Academy of Dermatology 2008;58(5):826-50.
2008: Elizabeth C A Smith; Christy Riddle; M Alan Menter; Mark Lebwohl
Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
International journal of dermatology 2008;47(5):514-8.
2008: Yongyin Wang; Xueyan Zhou; Elhav Weinstein; Billie Maryles; Yanzhen Zhang; Julian Moore; Dayuan Gao; David P Atencio; Barry S Rosenstein; Mark Lebwohl; Hong-Duo Chen; Ting Xiao; Huachen Wei
p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVA.
Photochemistry and photobiology 2008;84(2):444-9.
2008: Lily Clark; Mark Lebwohl
The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
Journal of the American Academy of Dermatology 2008;58(3):443-6.
2008: Mark Lebwohl; Jerry Bagel; Joel M Gelfand; Dafna Gladman; Kenneth B Gordon; Sylvia Hsu; Robert E Kalb; Alexa B Kimball; Neil J Korman; Gerald G Krueger; Philip J Mease; Warwick L Morison; Amy Paller; David M Pariser; Christopher T Ritchlin; Bruce E Strober; Abby S Van Voorhees; Gerald D Weinstein; Melodie Young; Liz Horn
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
Journal of the American Academy of Dermatology 2008;58(1):94-105.
2007: Elizabeth J Horn; Kathleen M Fox; Vaishali Patel; Chiun-Fang Chiou; Frank Dann; Mark Lebwohl
Association of patient-reported psoriasis severity with income and employment.
Journal of the American Academy of Dermatology 2007;57(6):963-71.
2007: Elizabeth J Horn; Kathleen M Fox; Vaishali Patel; Chiun-Fang Chiou; Frank Dann; Mark Lebwohl
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey.
Journal of the American Academy of Dermatology 2007;57(6):957-62.
2007: Mark Lebwohl; Luz E Colón
The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis.
Cutis; cutaneous medicine for the practitioner 2007;80(5 Suppl):29-40.
2007: Lily N Clark; Mark Lebwohl
Recent advances in medical dermatology.
International journal of dermatology 2007;46(10):1005-10.
2007: Dana Kazlow Stern; Stephanie Diamantis; Elizabeth Smith; Huachen Wei; Marsha Gordon; Wangui Muigai; Erin Laverne Moshier; Mark Lebwohl; Phyllis Spuls
Water content and other aspects of brittle versus normal fingernails.
Journal of the American Academy of Dermatology 2007;57(1):31-6.
2007: Annemarie Uliasz; Mark Lebwohl
Patient education and regular surveillance results in earlier diagnosis of second primary melanoma.
International journal of dermatology 2007;46(6):575-7.
2007: Mark Lebwohl; Lily Clark; Jacob Levitt
Therapy for head lice based on life cycle, resistance, and safety considerations.
Pediatrics 2007;119(5):965-74.
2007: Mark Lebwohl; Alan Menter; Jonathan Weiss; Scott D Clark; Javier Flores; Jerold Powers; Arthur K Balin; Steven Kempers; Robert J Glinert; Thomas Fleming; Yin Liu; Michael Graeber; David M Pariser
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
Journal of drugs in dermatology : JDD 2007;6(4):428-35.
2007: Joshua A Zeichner; Mark Lebwohl
Potential complications associated with the use of biologic agents for psoriasis.
Dermatologic clinics 2007;25(2):207-13, vii.
2007: Gerald G Krueger; Richard G B Langley; Craig L Leonardi; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Lisa T Dooley; Mark Lebwohl
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
The New England journal of medicine 2007;356(6):580-92.
2007: David M Pariser; Jerry Bagel; Joel M Gelfand; Neil J Korman; Christopher T Ritchlin; Bruce E Strober; Abby S Van Voorhees; Melodie Young; Sheila Rittenberg; Mark Lebwohl; Elizabeth J Horn
National Psoriasis Foundation clinical consensus on disease severity.
Archives of dermatology 2007;143(2):239-42.
2007: Mark Lebwohl; Linda Corvari
Compatibility of topical therapies for psoriasis: challenges and innovations.
Cutis; cutaneous medicine for the practitioner 2007;79(1 Suppl 2):5-10.
2007: Mark Lebwohl
Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris.
Cutis; cutaneous medicine for the practitioner 2007;79(1 Suppl 2):3-4.
2006: Caroline P Halverstam; Joshua Zeichner; Mark Lebwohl
Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature.
Journal of cutaneous medicine and surgery 2006;10(6):291-9.
2006: John Koo; Robin R Blum; Mark Lebwohl
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes.
Journal of the American Academy of Dermatology 2006;55(4):637-41.
2006: Julian O Moore; Yongyin Wang; William G Stebbins; Dayuan Gao; Xueyan Zhou; Robert Phelps; Mark Lebwohl; Huachen Wei
Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis.
Carcinogenesis 2006;27(8):1627-35.
2006: Suhail Hadi; Patricia Tinio; Khalid Al-Ghaithi; Haitham Al-Qari; Mohammad Al-Helalat; Mark Lebwohl; James Spencer
Treatment of vitiligo using the 308-nm excimer laser.
Photomedicine and laser surgery 2006;24(3):354-7.
2006: Elizabeth Smith; Marsha Gordon; Mark Lebwohl
Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report.
Cutis; cutaneous medicine for the practitioner 2006;77(6):361-4.
2006: Mark Lebwohl; Martin Kathryn
New roles for systemic retinoids.
Journal of drugs in dermatology : JDD 2006;5(5):406-9.
2006: Ashlee S Rigel; Mark Lebwohl
Hat-wearing patterns in persons attending baseball games.
Journal of the American Academy of Dermatology 2006;54(5):918-9.
2006: Clark C Otley; Thomas Stasko; Whitney D Tope; Mark Lebwohl
Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2006;32(4):562-8.
2006: Wayne Carey; Scott Glazer; Alice B Gottlieb; Mark Lebwohl; Craig L Leonardi; Alan Menter; Kim A Papp; Amy Chen Rundle; Darryl Toth
Relapse, rebound, and psoriasis adverse events: an advisory group report.
Journal of the American Academy of Dermatology 2006;54(4 Suppl 1):S171-81.
2006: Franziska Ringpfeil; Kelly McGuigan; Lauren Fuchsel; Heidi Kozic; Margarita Larralde; Mark Lebwohl; Jouni Uitto
Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity.
The Journal of investigative dermatology 2006;126(4):782-6.
2006: Joshua A Zeichner; Dana W K Stern; Mark Lebwohl
Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept.
Journal of the American Academy of Dermatology 2006;54(3 Suppl 2):S120-1.
2006: Mark Lebwohl; Tara Gower
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
MedGenMed : Medscape general medicine 2006;8(4):8.
2006: Kathie Koo; Harold Brem; Mark Lebwohl
Pyoderma gangrenosum versus chronic venous ulceration: comparison of diagnostic features.
Journal of cutaneous medicine and surgery 2006;10(1):26-30.
2006: Alan Menter; Jennifer Clay Cather; Diane Baker; Harold F Farber; Mark Lebwohl; Mohamed Darif
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
Journal of the American Academy of Dermatology 2006;54(1):61-3.
2005: Mark Lebwohl; Lisa G Herrmann
Impaired skin barrier function in dermatologic disease and repair with moisturization.
Cutis; cutaneous medicine for the practitioner 2005;76(6 Suppl):7-12.
2005: David M Pariser; Kenneth B Gordon; Kim A Papp; Craig L Leonardi; Paul Kwon; Peter G Compton; Amy Chen Rundle; Patricia A Walicke; Mark Lebwohl
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
Journal of cutaneous medicine and surgery 2005;9(6):303-12.
2005: Mark Lebwohl
Advances in psoriasis.
Archives of dermatology 2005;141(12):1589-90.
2005: Vicky Kwan Wong; Mark Lebwohl
Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
Expert opinion on biological therapy 2005;5(11):1505-13.
2005: Dayuan Gao; Yunjing Luo; Denise Guevara; Yongyin Wang; Mei Rui; Billie Goldwyn; Yuhun Lu; Elizabeth C A Smith; Mark Lebwohl; Huachen Wei
Benzo[a]pyrene and its metabolites combined with ultraviolet A synergistically induce 8-hydroxy-2'-deoxyguanosine via reactive oxygen species.
Free radical biology & medicine 2005;39(9):1177-83.
2005: Daniel W Sherer; Giselle Singer; Jaime Uribarri; Robert G Phelps; Allen N Sapadin; K Bailey Freund; Lawrence Yanuzzi; Wayne Fuchs; Mark Lebwohl
Oral phosphate binders in the treatment of pseudoxanthoma elasticum.
Journal of the American Academy of Dermatology 2005;53(4):610-5.
2005: Mark Lebwohl; Amy Freeman; M Shane Chapman; Steven Feldman; Jennifer Hartle; Alice Henning
Proven efficacy of tacrolimus for facial and intertriginous psoriasis.
Archives of dermatology 2005;141(9):1154.
2005: Sara Miksch; Amanda Lumsden; Ulf P Guenther; Dorothee Foernzler; Stéphanie Christen-Zäch; Carol Daugherty; Raj Kumar S Ramesar; Mark Lebwohl; Daniel Hohl; Kenneth H Neldner; Klaus Lindpaintner; Robert I Richards; Berthold Struk
Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutations in ABCC6.
Human mutation 2005;26(3):235-48.
2005: Yongyin Wang; Dayuan Gao; David P Atencio; Evangeline Perez; Rao N Saladi; Julian Moore; Denise Guevara; Barry S Rosenstein; Mark Lebwohl; Huachen Wei
Combined subcarcinogenic benzo[a]pyrene and UVA synergistically caused high tumor incidence and mutations in H-ras gene, but not p53, in SKH-1 hairless mouse skin.
International journal of cancer. Journal international du cancer 2005;116(2):193-9.
2005: Mark Lebwohl; Robin Blum; Eric Berkowitz; Dennis Kim; Ralph Zitnik; Cheri Osteen; Wayne Jack Wallis
No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years.
Archives of dermatology 2005;141(7):861-4.
2005: Mark Lebwohl
A clinician's paradigm in the treatment of psoriasis.
Journal of the American Academy of Dermatology 2005;53(1 Suppl 1):S59-69.
2005: Carin H Gribetz; Robin Blum; Christopher Brady; Steven R Cohen; Mark Lebwohl
An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
Journal of the American Academy of Dermatology 2005;53(1):73-5.
2005: Marc C Hochberg; Mark Lebwohl; Scott Plevy; Kathryn F Hobbs; David E Yocum
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
Seminars in arthritis and rheumatism 2005;34(6):819-36.
2005: Stephen P McKenna; Mark Lebwohl; Kristijan Kahler
Development of the US PSORIQoL: a psoriasis-specific measure of quality of life.
International journal of dermatology 2005;44(6):462-9.
2005: Debra Breneman; Alan B Fleischer; David Kaplan; Mark Lebwohl; Bruce Miller; David M Pariser; Toivo Rist; Leonard J Swinyer; Yin Liu; Valerie Foley
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.
Journal of drugs in dermatology : JDD 2005;4(3):330-6.
2005: Jennifer Soung; Wangui Muigai; Nilam Amin; Dana K Stern; Mark Lebwohl
A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA).
Journal of drugs in dermatology : JDD 2005;4(3):290-4.
2005: Amy S Paller; Mark Lebwohl; Alan B Fleischer; Richard J Antaya; Richard G Langley; Robert S Kirsner; Robin R Blum; M Joyce Rico; Eileen Jaracz; Andrew Crowe; Gregory J Linowski
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies.
Journal of the American Academy of Dermatology 2005;52(5):810-22.
2005: Dana Kazlow Stern; Jackie M Tripp; Vincent C Ho; Mark Lebwohl
The use of systemic immune moderators in dermatology: an update.
Dermatologic clinics 2005;23(2):259-300.
2005: Benjamin Schwartz; Mark Lebwohl
Complications of the smallpox vaccine.
International journal of dermatology 2005;44(4):289-92.
2005: Mark Lebwohl; P T Ting; John Y M Koo
Psoriasis treatment: traditional therapy.
Annals of the rheumatic diseases 2005;64 Suppl 2():ii83-6.
2005: Sewon Kang; Wilma F Bergfeld; Alice B Gottlieb; Janet Hickman; John Humeniuk; Steven Kempers; Mark Lebwohl; Nicholas Lowe; Amy McMichael; James Milbauer; Tania Phillips; Jerold Powers; David Rodriguez; Ronald Savin; Joel Shavin; Daniel Sherer; Nancy Silvis; Richard Weinstein; Jonathan Weiss; Craig Hammerberg; Gary J Fisher; Marge Nighland; Rachel Grossman; Judit Nyirady
Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial.
American journal of clinical dermatology 2005;6(4):245-53.
2005: Mark Lebwohl
Use of etanercept in the dermatology setting. A review.
American journal of clinical dermatology 2005;6(1):49-59.
2005: Sumedha Lamba; Anna Krishtul; Mei-Heng Tan; Mark Lebwohl
Acanthosis nigricans in a plaque of scleredema on the back of a diabetic patient: a case report.
International journal of dermatology 2005;44(1):45-7.
2004: Alice B Gottlieb; Kenneth B Gordon; Mark Lebwohl; Ivor Caro; Patricia A Walicke; Nicole Li; Craig L Leonardi
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Journal of drugs in dermatology : JDD 2004;3(6):614-24.
2004: Julian O Moore; Sapna R Palep; Rao N Saladi; Dayuan Gao; Yongyin Wang; Robert G Phelps; Mark Lebwohl; Huachen Wei
Effects of ultraviolet B exposure on the expression of proliferating cell nuclear antigen in murine skin.
Photochemistry and photobiology 2004;80(3):587-95.
2004: Carin Gribetz; Mark Ling; Mark Lebwohl; David M Pariser; Zoe Diana Draelos; Alice B Gottlieb; Nardo Zaias; Diana M Chen; Anne Parneix-Spake; Thomas Hultsch; Alan Menter
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Journal of the American Academy of Dermatology 2004;51(5):731-8.
2004: Mark Lebwohl; Amy Krupnick Freeman; M Shane Chapman; Steven R Feldman; Jennifer E Hartle; Alice Henning
Tacrolimus ointment is effective for facial and intertriginous psoriasis.
Journal of the American Academy of Dermatology 2004;51(5):723-30.
2004: David S Aaronson; Mark Lebwohl
Review of therapy of psoriasis: the prebiologic armamentarium.
Dermatologic clinics 2004;22(4):379-88, viii.
2004: Fiza Singh; Mark Lebwohl
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Journal of the American Academy of Dermatology 2004;51(4):570-3.
2004: Mary M Prendergast; William Abramovits; Mark Boguniewicz; Mark Lebwohl; Michael Tokar; Kuo B Tong
Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatology.
The Journal of investigative dermatology 2004;123(3):452-4.
2004: Rao N Saladi; Fiza Singh; Huachen Wei; Mark Lebwohl; Robert G Phelps
Use of Ber-EP4 protein in recurrent metastatic basal cell carcinoma: a case report and review of the literature.
International journal of dermatology 2004;43(8):600-3.
2004: Vicky Kwan Wong; Brian Fuchs; Mark Lebwohl
Overview on desonide 0.05%: a clinical safety profile.
Journal of drugs in dermatology : JDD 2004;3(4):393-7.
2004: Mark Lebwohl; Todd Plott
Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial.
International journal of dermatology 2004;43 Suppl 1():17-20.
2004: Mark Lebwohl
Innovations in the treatment of psoriasis.
Journal of the American Academy of Dermatology 2004;51(1 Suppl):S40-1.
2004: Suhail Hadi; James M Spencer; Mark Lebwohl
The use of the 308-nm excimer laser for the treatment of vitiligo.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2004;30(7):983-6.
2004: Mark Lebwohl; Scott Dinehart; David Whiting; Peter K Lee; Naji Tawfik; Joseph L Jorizzo; James H Lee; Terry L Fox
Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
Journal of the American Academy of Dermatology 2004;50(5):714-21.
2004: Amy Krupnick Freeman; Janet B Serle; Paul Vanveldhuisen; Leah Lind; Jan Clarke; Giselle Singer; Mark Lebwohl
Tacrolimus ointment in the treatment of eyelid dermatitis.
Cutis; cutaneous medicine for the practitioner 2004;73(4):267-71.
2004: Alice B Gottlieb; Sewon Kang; Kenneth G Linden; Mark Lebwohl; Alan Menter; Ahsan A Abdulghani; Michael T Goldfarb; Nicole Chieffo; Mark C Totoritis
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
Clinical immunology (Orlando, Fla.) 2004;111(1):28-37.
2004: John Koo; Ernest Lee; Chai Sue Lee; Mark Lebwohl
Psoriasis.
Journal of the American Academy of Dermatology 2004;50(4):613-22.
2004: Mark Lebwohl; Alan Menter; John Koo; Steven R Feldman
Combination therapy to treat moderate to severe psoriasis.
Journal of the American Academy of Dermatology 2004;50(3):416-30.
2004: Aaron Fuchs; Jodi Fiedler; Mark Lebwohl; Allen N Sapadin; Donald Rudikoff; Albert Lefkovits; Neal Schultz; Sylvie Khorenian; Lenore Kakita
Frequency of culture-proven dermatophyte infection in patients with suspected tinea pedis.
The American journal of the medical sciences 2004;327(2):77-8.
2004: William G Stebbins; Mark Lebwohl
Biologics in combination with nonbiologics: efficacy and safety.
Dermatologic therapy 2004;17(5):432-40.
2003: Ethan G Rigel; Mark Lebwohl; Adam C Rigel; Darrell S Rigel
Daily UVB exposure levels in high-school students measured with digital dosimeters.
Journal of the American Academy of Dermatology 2003;49(6):1112-4.
2003: Mark Lebwohl; Stephen K Tyring; Tiffani K Hamilton; Darryl Toth; Scott Glazer; Naji H Tawfik; Patricia A Walicke; Wolfgang Dummer; Xiaolin Wang; Marvin Garovoy; David M Pariser
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
The New England journal of medicine 2003;349(21):2004-13.
2003: Huachen Wei; Rao N Saladi; Yuhun Lu; Yan Wang; Sapna R Palep; Julian Moore; Robert Phelps; Eileen Q Shyong; Mark Lebwohl
Isoflavone genistein: photoprotection and clinical implications in dermatology.
The Journal of nutrition 2003;133(11 Suppl 1):3811S-3819S.
2003: Jeffrey P Callen; Gerald G Krueger; Mark Lebwohl; Elizabeth I McBurney; Philip J Mease; Alan Menter; Amy S Paller; David M Pariser; Michael E Weinblatt; Gail Zimmerman
AAD consensus statement on psoriasis therapies.
Journal of the American Academy of Dermatology 2003;49(5):897-9.
2003: Hassan Galadari; Mark Lebwohl
Pseudoxanthoma elasticum: Temporary treatment of chin folds and lines with injectable collagen.
Journal of the American Academy of Dermatology 2003;49(5 Suppl):S265-6.
2003: Fiza Singh; Dayuan Gao; Mark Lebwohl; Huachen Wei
Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells.
Cancer letters 2003;200(2):115-21.
2003: Vicky Kwan Wong; Mark Lebwohl
The use of alefacept in the treatment of psoriasis.
Skin therapy letter 2003;8(6):1-2, 7.
2003: Mark Lebwohl; John Quijije; Jean Gilliard; Thierry Rollin; Oliver Watts
Topical calcitriol is degraded by ultraviolet light.
The Journal of investigative dermatology 2003;121(3):594-5.
2003: Mark Lebwohl
Combining the new biologic agents with our current psoriasis armamentarium.
Journal of the American Academy of Dermatology 2003;49(2 Suppl):S118-24.
2003: Dana W Kazlow; David Federgrun; Stephen Kurtin; Mark Lebwohl
Cutaneous ulceration caused by methotrexate.
Journal of the American Academy of Dermatology 2003;49(2 Suppl Case Reports):S197-8.
2003: Thomas Ruzicka; Till Assmann; Mark Lebwohl
Potential future dermatological indications for tacrolimus ointment.
European journal of dermatology : EJD 2003;13(4):331-42.
2003: Vicky Kwan Wong; Christine Della Croce; Sara Schonfeld; Anthony M Mastrangelo; Mark Lebwohl
Use and abuse of topical corticosteroids in infections of the skin and related structures.
Journal of drugs in dermatology : JDD 2003;2(3):268-76.
2003: Mark Lebwohl; Enno Christophers; Richard Langley; Jean P Ortonne; Janet Roberts; Christopher E M Griffiths
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Archives of dermatology 2003;139(6):719-27.
2003: Marvin J Rapaport; Mark Lebwohl
Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome.
Clinics in dermatology 2003;21(3):201-14.
2003: Gerald D Weinstein; John Y M Koo; Gerald G Krueger; Mark Lebwohl; Nicholas J Lowe; M Alan Menter; Deborah A Lew-Kaya; John Sefton; John R Gibson; Patricia S Walker
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Journal of the American Academy of Dermatology 2003;48(5):760-7.
2003: Eileen Q Shyong; Yuhun Lu; Amy Goldstein; Mark Lebwohl; Huachen Wei
Synergistic enhancement of H2O2 production in human epidermoid carcinoma cells by Benzo[a]pyrene and ultraviolet A radiation.
Toxicology and applied pharmacology 2003;188(2):104-9.
2003: Mark Lebwohl
Psoriasis.
Lancet 2003;361(9364):1197-204.
2003: Rao N Saladi; Lisa Austin; Dayuan Gao; Yuhun Lu; Robert Phelps; Mark Lebwohl; Huachen Wei
The combination of benzo[a]pyrene and ultraviolet A causes an in vivo time-related accumulation of DNA damage in mouse skin.
Photochemistry and photobiology 2003;77(4):413-9.
2003: Mark Lebwohl; Eve Lebwohl; Lionel Bercovitch
Prominent mental (chin) crease: a new sign of pseudoxanthoma elasticum.
Journal of the American Academy of Dermatology 2003;48(4):620-2.
2003: Amy Krupnick Freeman; Gregory J Linowski; Christopher Brady; Leah Lind; Paul Vanveldhuisen; Giselle Singer; Mark Lebwohl
Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.
Journal of the American Academy of Dermatology 2003;48(4):564-8.
2003: Charles Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Amy S Paller; Seth R Stevens; Diane L Whitaker-Worth; Kuo B Tong
Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis.
Journal of the American Academy of Dermatology 2003;48(4):553-63.
2003: Jean-Paul Ortonne; Mark Lebwohl; Christopher Em Griffiths
Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
European journal of dermatology : EJD 2003;13(2):117-23.
2003: Hassan Galadari; Brian Fuchs; Mark Lebwohl
Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
International journal of dermatology 2003;42(3):231-7.
2003: Lionel Bercovitch; Barbara Schepps; Susan Koelliker; Cynthia Magro; Sharon F Terry; Mark Lebwohl
Mammographic findings in pseudoxanthoma elasticum.
Journal of the American Academy of Dermatology 2003;48(3):359-66.
2003: Zsuzsanna Fazekas; Dayuan Gao; Rao N Saladi; Yuhun Lu; Mark Lebwohl; Huachen Wei
Protective effects of lycopene against ultraviolet B-induced photodamage.
Nutrition and cancer 2003;47(2):181-7.
2003: Mark Lebwohl; Alan Menter; John Koo; Steven Feldman
Case studies in severe psoriasis: A clinical strategy.
The Journal of dermatological treatment 2003;14 Suppl 2():26-46.
2003: Phyllis Spuls; Suhail Hadi; L Rivera; Mark Lebwohl
Retrospective analysis of the treatment of psoriasis of the palms and soles.
The Journal of dermatological treatment 2003;14 Suppl 2():21-5.
2003: Phyllis Spuls; M Rozenblit; Mark Lebwohl
Retrospective study of the efficacy of narrowband UVB and acitretin.
The Journal of dermatological treatment 2003;14 Suppl 2():17-20.
2003: S Maryles; M Rozenblit; Mark Lebwohl
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.
The Journal of dermatological treatment 2003;14 Suppl 2():7-16.
2003: Mark Lebwohl; C Tannis; D Carrasco
Acitretin suppression of squamous cell carcinoma: case report and literature review.
The Journal of dermatological treatment 2003;14 Suppl 2():3-6.
2003: Charles Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Seth R Stevens; Diane L Whitaker-Worth; Kuo B Tong
Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema.
PharmacoEconomics 2003;21(12):875-83.
2003: Ethan G Rigel; Mark Lebwohl; Adam C Rigel; Darrell S Rigel
Ultraviolet radiation in alpine skiing: magnitude of exposure and importance of regular protection.
Archives of dermatology 2003;139(1):60-2.
2002: Eileen Q Shyong; Peter Gorevic; Mark Lebwohl; Robert G Phelps
Reactive angioendotheliomatosis and sarcoidosis.
International journal of dermatology 2002;41(12):894-7.
2002: Huachen Wei; Xueshu Zhang; Yan Wang; Mark Lebwohl
Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein.
Cancer letters 2002;185(1):21-9.
2002: Mark Lebwohl
Vitamin D and topical therapy.
Cutis; cutaneous medicine for the practitioner 2002;70(5 Suppl):5-8.
2002: Mei-Heng Tan; Stacie L Meador; Giselle Singer; Mark Lebwohl
An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas.
International journal of dermatology 2002;41(11):804-9.
2002: Alice B Gottlieb; Mark Lebwohl; Mark C Totoritis; Ahsan A Abdulghani; Steve R Shuey; Patricia Romano; Umesh Chaudhari; Roberta S Allen; Richard G Lizambri
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody.
Journal of the American Academy of Dermatology 2002;47(5):692-700.
2002: Daniel W Sherer; Mark Lebwohl
6-thioguanine in the treatment of psoriasis: a case report and literature review.
Journal of cutaneous medicine and surgery 2002;6(6):546-50.
2002: Andrea N Persaud; Eleonora Shamuelova; Daniel Sherer; Wendy Lou; Giselle Singer; Christina Cervera; Sumedha Lamba; Mark Lebwohl
Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis.
Journal of the American Academy of Dermatology 2002;47(4):553-6.
2002: Andrea Persaud; Mark Lebwohl
Imiquimod cream in the treatment of actinic keratoses.
Journal of the American Academy of Dermatology 2002;47(4 Suppl):S236-9.
2002: Dana Kaslow Stern; Mark Lebwohl
Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Journal of drugs in dermatology : JDD 2002;1(2):134-6.
2002: Mark Lebwohl; Daniel Sherer; Ken Washenik; Gerald G Krueger; Alan Menter; John Koo; Steven R Feldman
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
International journal of dermatology 2002;41(5):269-74.
2002: Mark Lebwohl
New developments in the treatment of psoriasis.
Archives of dermatology 2002;138(5):686-8.
2002: Carin H Endzweig-Gribetz; Christopher Brady; Charles Lynde; Debra Sibbald; Mark Lebwohl
Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies.
Journal of cutaneous medicine and surgery 2002;6(3 Suppl):12-6.
2002: Susan Bershad; Giselle Kranjac Singer; Janice E Parente; Mei-Heng Tan; Daniel W Sherer; Andrea N Persaud; Mark Lebwohl
Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel.
Archives of dermatology 2002;138(4):481-9.
2002: Charles Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Seth R Stevens; Diane L Whitaker-Worth; J Wang Cheng; Kuo B Tong
Cost of atopic dermatitis and eczema in the United States.
Journal of the American Academy of Dermatology 2002;46(3):361-70.
2002: Mark Lebwohl
Should we switch from combination UVA/UVB phototherapy units to narrowband UVB?
Photodermatology, photoimmunology & photomedicine 2002;18(1):44-6; discussion 47-9.
2002: Eileen Q Shyong; Yuhun Lu; Alison Lazinsky; Rao N Saladi; Robert G Phelps; Lisa M Austin; Mark Lebwohl; Huachen Wei
Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage.
Carcinogenesis 2002;23(2):317-21.
2001: Mark Lebwohl; S Ali
Treatment of psoriasis. Part 2. Systemic therapies.
Journal of the American Academy of Dermatology 2001;45(5):649-61; quiz 662-4.
2001: Mark Lebwohl; L Drake; Alan Menter; John Koo; A B Gottlieb; M Zanolli; Melodie Young; P McClelland
Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis.
Journal of the American Academy of Dermatology 2001;45(4):544-53.
2001: Mark Lebwohl; S Ali
Treatment of psoriasis. Part 1. Topical therapy and phototherapy.
Journal of the American Academy of Dermatology 2001;45(4):487-98; quiz 499-502.
2001: Ronnit Hamuy Stein; Mark Lebwohl
Acne therapy: clinical pearls.
Seminars in cutaneous medicine and surgery 2001;20(3):184-9.
2001: Mei-Heng Tan; Mark Lebwohl; A C Esser; H Wei
The penetration of 0.005% fluticasone propionate ointment in eyelid skin.
Journal of the American Academy of Dermatology 2001;45(3):392-6.
2001: Mei-Heng Tan; M Gordon; O Lebwohl; J George; Mark Lebwohl
Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Archives of dermatology 2001;137(7):930-3.
2001: R R Blum; A Rahimizadeh; Nataline B Kardon; Mark Lebwohl; H Wei
Genital lentigines in a 6-year-old boy with a family history of Cowden's disease: clinical and genetic evidence of the linkage between Bannayan-Riley-Ruvacalba syndrome and Cowden's disease.
Journal of cutaneous medicine and surgery 2001;5(3):228-30.
2001: Mark Lebwohl; C R Daniel; James J Leyden; M Mormon; Joel Shavin; Eduardo Tschen; J Weiss; J Zone
Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis.
International journal of dermatology 2001;40(5):358-60.
2001: K Kuroda; Allen N Sapadin; T Shoji; Raul Fleischmajer; Mark Lebwohl
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis.
The Journal of investigative dermatology 2001;116(5):713-20.
2001: S Lamba; Mark Lebwohl
Combination therapy with vitamin D analogues.
The British journal of dermatology 2001;144 Suppl 58():27-32.
2001: Mark Lebwohl; Boni E Elewski; D Eisen; Ronald Savin
Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris.
Cutis; cutaneous medicine for the practitioner 2001;67(3):261-6.
2001: Gerald Krueger; J Koo; Mark Lebwohl; Alan Menter; Robert S Stern; Tara Rolstad
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
Archives of dermatology 2001;137(3):280-4.
2001: D W Sherer; L Bercovitch; Mark Lebwohl
Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring.
Journal of the American Academy of Dermatology 2001;44(3):534-7.
2001: Mark Lebwohl; K Lombardi; M H Tan
Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments.
International journal of dermatology 2001;40(1):64-6.
2001: Mark Lebwohl; S R Feldman; R Walther; J Shelk; P Morgan; S W Gutkin
Clinical management of psoriasis: principles and practice.
Cutis; cutaneous medicine for the practitioner 2001;67(1 Suppl):1-15.
2001: Mark Lebwohl; Mei-Heng Tan; S L Meador; Giselle Singer
Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas.
Journal of the American Academy of Dermatology 2001;44(1):77-82.
2000: Raul Fleischmajer; K Kuroda; Rachel B Hazan; Ronald E Gordon; Mark Lebwohl; Allen N Sapadin; Fernando Unda; N Iehara; Yoshihiko Yamada
Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2.
The Journal of investigative dermatology 2000;115(5):771-7.
2000: Alice B Gottlieb; Mark Lebwohl; S Shirin; A Sherr; Patricia Gilleaudeau; G Singer; G Solodkina; R Grossman; E Gisoldi; S Phillips; H M Neisler; James G Krueger
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study.
Journal of the American Academy of Dermatology 2000;43(4):595-604.
2000: R Buka; Huachen Wei; Allen N Sapadin; J Mauch; Mark Lebwohl; Donald Rudikoff
Pseudoxanthoma elasticum and calcinosis cutis.
Journal of the American Academy of Dermatology 2000;43(2 Pt 1):312-5.
2000: Gerald G Krueger; Steven R Feldman; C Camisa; Madeleine Duvic; James T Elder; Alice B Gottlieb; J Koo; J G Krueger; Mark Lebwohl; Nicholas Lowe; Alan Menter; Warwick L Morison; J H Prystowsky; Jerome L Shupack; J R Taylor; Gerald D Weinstein; T L Barton; Tara Rolstad; R M Day
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
Journal of the American Academy of Dermatology 2000;43(2 Pt 1):281-5.
2000: Mark Lebwohl
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
Journal of the American Academy of Dermatology 2000;43(2 Pt 3):S43-6.
2000: D Hecker; J Worsley; G Yueh; Mark Lebwohl
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Journal of the American Academy of Dermatology 2000;42(6):1008-11.
2000: Franziska Ringpfeil; Mark Lebwohl; Angela M Christiano; Jouni Uitto
Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(11):6001-6.
2000: Alice Gottlieb; James G Krueger; R Bright; Mark Ling; Mark Lebwohl; Sewon Kang; S Feldman; M Spellman; K Wittkowski; H D Ochs; P Jardieu; R Bauer; Mark White; Russell Dedrick; Marvin Garovoy
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.
Journal of the American Academy of Dermatology 2000;42(3):428-35.
2000: L Cai; Berthold Struk; Mark D Adams; W Ji; T Haaf; HL Kang; S H Dho; X Xu; F Ringpfeil; J Nancarrow; S Zäch; L Schaen; M Stumm; T Niu; J Chung; K Lunze; B Verrecchia; lowell goldsmith; D Viljoen; Luis Figuera; W Fuchs; Mark Lebwohl; Jouni Uitto; R Richards; Daniel Hohl; Raj Kumar S Ramesar
A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure.
Journal of molecular medicine (Berlin, Germany) 2000;78(1):36-46.
2000: Zsolt Urbán; Simone Peyrol; H Plauchu; M T Zabot; Mark Lebwohl; K Schilling; M Green; Charles D Boyd; K Csiszár
Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype.
Pediatric dermatology 2000;17(1):12-20.
2000: Mark Lebwohl
Advances in psoriasis therapy.
Dermatologic clinics 2000;18(1):13-9, vii.
1999: D Hecker; J Worsley; G Yueh; K Kuroda; Mark Lebwohl
Interactions between tazarotene and ultraviolet light.
Journal of the American Academy of Dermatology 1999;41(6):927-30.
1999: Olivier Le Saux; Zsolt Urban; Harald HH Goring; Katalin Csiszar; F Michael Pope; A Richards; Ivonne Pasquali-Ronchetti; Sharon F Terry; Lionel Bercovitch; Mark Lebwohl; M Breuning; P van den Berg; Lilian Kornet; N Doggett; J Ott; Paulus T V M de Jong; Arthur A B Bergen; Charles D Boyd
Pseudoxanthoma elasticum maps to an 820-kb region of the p13.1 region of chromosome 16.
Genomics 1999;62(1):1-10.
1999: Barry S Rosenstein; Robert G Phelps; Martin A Weinstock; Jonine L Bernstein; Marsha L Gordon; Donald Rudikoff; I Kantor; R Shelton; Mark Lebwohl
p53 mutations in basal cell carcinomas arising in routine users of sunscreens.
Photochemistry and photobiology 1999;70(5):798-806.
1999: Mark Lebwohl
Acitretin in combination with UVB or PUVA.
Journal of the American Academy of Dermatology 1999;41(3 Pt 2):S22-4.
1999: S J Salasche; Mark Lebwohl
Clinical pearl: vitamin E (alpha-tocopherol), 800 IU daily, may reduce retinoid toxicity.
Journal of the American Academy of Dermatology 1999;41(2 Pt 1):260.
1999: Z Liu; Yuhun Lu; Mark Lebwohl; Huachen Wei
PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2'-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells.
Free radical biology & medicine 1999;27(1-2):127-33.
1999: John Koo; Mark Lebwohl
Duration of remission of psoriasis therapies.
Journal of the American Academy of Dermatology 1999;41(1):51-9.
1999: Donald Rudikoff; J Baral; Mark Lebwohl
Psoriasis and Crohn's disease.
The Mount Sinai journal of medicine, New York 1999;66(3):206.
1999: M C Sicari; Mark Lebwohl; J Baral; P Wexler; Ronald E Gordon; Robert G Phelps
Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy.
Journal of the American Academy of Dermatology 1999;40(2 Pt 2):290-3.
1999: Mark Lebwohl; J M Gelfand; M H Tan
Clinically significant therapeutic interactions for the practicing dermatologist.
Advances in dermatology 1999;14():1-26; discussion 27.
1999: D W Sherer; Allen N Sapadin; Mark Lebwohl
Pseudoxanthoma elasticum: an update.
Dermatology (Basel, Switzerland) 1999;199(1):3-7.
1999: Mark Lebwohl
The role of salicylic acid in the treatment of psoriasis.
International journal of dermatology 1999;38(1):16-24.
1998: Mark Lebwohl; Y Poulin
Tazarotene in combination with topical corticosteroids.
Journal of the American Academy of Dermatology 1998;39(4 Pt 2):S139-43.
1998: Mark Lebwohl; Debra L Breneman; Bernard S Goffe; J R Grossman; Mark R Ling; J Milbauer; S H Pincus; R G Sibbald; Leonard J Swinyer; Gerald D Weinstein; Deborah A Lew-Kaya; JC Lue; John R Gibson; John Sefton
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
Journal of the American Academy of Dermatology 1998;39(4 Pt 1):590-6.
1998: Y Wang; Barry S Rosenstein; S Goldwyn; X Zhang; Mark Lebwohl; Huachen Wei
Differential regulation of P53 and Bcl-2 expression by ultraviolet A and B.
The Journal of investigative dermatology 1998;111(3):380-4.
1998: Mark Lebwohl; Charles Ellis; A Gottlieb; John Koo; G Krueger; K Linden; J Shupack; G Weinstein
Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.
Journal of the American Academy of Dermatology 1998;39(3):464-75.
1998: Mark Lebwohl; A Yoles; K Lombardi; W Lou
Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
Journal of the American Academy of Dermatology 1998;39(3):447-50.
1998: Huachen Wei; R Bowen; Xueshu Zhang; Mark Lebwohl
Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice.
Carcinogenesis 1998;19(8):1509-14.
1998: Allen N Sapadin; Mark Lebwohl; S A Teich; Robert G Phelps; Damian P DiCostanzo; Steven R Cohen
Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks--apparent regression with hemodialysis.
Journal of the American Academy of Dermatology 1998;39(2 Pt 2):338-44.
1998: Z Liu; Yuhun Lu; Barry S Rosenstein; Mark Lebwohl; Huachen Wei
Benzo[a]pyrene enhances the formation of 8-hydroxy-2'-deoxyguanosine by ultraviolet A radiation in calf thymus DNA and human epidermoid carcinoma cells.
Biochemistry 1998;37(28):10307-12.
1998: Donald Rudikoff; Mark Lebwohl
Atopic dermatitis.
Lancet 1998;351(9117):1715-21.
1998: Huachen Wei; Q Cai; L Tian; Mark Lebwohl
Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo.
Carcinogenesis 1998;19(6):1013-8.
1998: K Nichols; N Desai; Mark Lebwohl
Effective sunscreen ingredients and cutaneous irritation in patients with rosacea.
Cutis; cutaneous medicine for the practitioner 1998;61(6):344-6.
1998: B Patel; S Siskin; R Krazmien; Mark Lebwohl
Compatibility of calcipotriene with other topical medications.
Journal of the American Academy of Dermatology 1998;38(6 Pt 1):1010-1.
1998: Mark R Ling; Leonard J Swinyer; Michael Jarratt; L Falo; E W Monroe; M Tharp; J Kalivas; Gerald D Weinstein; R G Asarch; LA Drake; Ann Martin; James J Leyden; Joel Cook; David M Pariser; Robert J Pariser; Bruce H Thiers; Mark Lebwohl; DE Babel; Daniel M Stewart; W H Eaglstein; V Falanga; H Irving Katz; Wilma F Bergfeld; Jon M Hanifin; M R Young
Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail.
Journal of the American Academy of Dermatology 1998;38(6 Pt 2):S95-102.
1998: Huachen Wei; Q Ca; Ronald O Rahn; X Zhang; Y Wang; Mark Lebwohl
DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage.
Biochemistry 1998;37(18):6485-90.
1998: Mark Lebwohl; E Ast; J P Callen; S I Cullen; S R Hong; C L Kulp-Shorten; Nicholas J Lowe; Tania Phillips; T Rosen; D I Wolf; J M Quell; John Sefton; JC Lue; John R Gibson; RA Chandraratna
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
Journal of the American Academy of Dermatology 1998;38(5 Pt 1):705-11.
1998: Jouni Uitto; Charles D Boyd; Mark Lebwohl; A N Moshell; Joel Rosenbloom; Sharon F Terry
International Centennial Meeting on Pseudoxanthoma Elasticum: progress in PXE research.
The Journal of investigative dermatology 1998;110(5):840-2.
1998: Yan Wang; Xueshu Zhang; Mark Lebwohl; V DeLeo; Huachen Wei
Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein.
Carcinogenesis 1998;19(4):649-54.
1998: M S Hecker; Mark Lebwohl
Recalcitrant pyoderma gangrenosum: treatment with thalidomide.
Journal of the American Academy of Dermatology 1998;38(3):490-1.
1998: Mark Lebwohl
Clinical efficacy and safety of tazarotene: optimizing clinical results.
Cutis; cutaneous medicine for the practitioner 1998;61(2 Suppl):27-9.
1998: Mark Lebwohl
New horizons in the management of psoriasis: introduction.
Cutis; cutaneous medicine for the practitioner 1998;61(2 Suppl):7.
1998: Mark Lebwohl; M H Tan
Psoriasis and stress.
Lancet 1998;351(9096):82.
1997: Mark Lebwohl
Topical application of calcipotriene and corticosteroids: combination regimens.
Journal of the American Academy of Dermatology 1997;37(3 Pt 2):S55-8.
1997: JL Jorizzo; K Magee; Daniel M Stewart; Mark Lebwohl; R Rajagopalan; J J Brown
Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
Cutis; cutaneous medicine for the practitioner 1997;60(1):55-60.
1997: Mark Lebwohl; D Hecker; J Martinez; Allen N Sapadin; B Patel
Interactions between calcipotriene and ultraviolet light.
Journal of the American Academy of Dermatology 1997;37(1):93-5.
1997: J S Sadeh; Donald Rudikoff; Marsha L Gordon; J Bowden; B D Goldman; Mark Lebwohl
Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome.
Archives of dermatology 1997;133(6):747-50.
1997: D Hecker; Mark Lebwohl
Topical calcipotriene in combination with UVB phototherapy for psoriasis.
International journal of dermatology 1997;36(4):302-3.
1997: A M Freedman; Robert G Phelps; Mark Lebwohl
Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient.
International journal of dermatology 1997;36(3):205-7.
1997: Mark Lebwohl
New treatments for alopecia areata.
Lancet 1997;349(9047):222-3.
1997: Xueshu Zhang; Barry S Rosenstein; Yongyin Wang; Mark Lebwohl; Huachen Wei
Identification of possible reactive oxygen species involved in ultraviolet radiation-induced oxidative DNA damage.
Free radical biology & medicine 1997;23(7):980-5.
1997: Xueshu Zhang; Barry S Rosenstein; Yan Wang; Mark Lebwohl; D M Mitchell; Huachen Wei
Induction of 8-oxo-7,8-dihydro-2'-deoxyguanosine by ultraviolet radiation in calf thymus DNA and HeLa cells.
Photochemistry and photobiology 1997;65(1):119-24.
1996: David M Pariser; Robert J Pariser; Debra L Breneman; Mark Lebwohl; R Kalb; J Moore; H Moss; C Parker; VC Fiedler
Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study.
Archives of dermatology 1996;132(12):1527.
1996: A Yoles; R Phelps; Mark Lebwohl
Pseudoxanthoma elasticum and pregnancy.
Cutis; cutaneous medicine for the practitioner 1996;58(2):161-4.
1996: Mark Lebwohl; S B Siskin; W Epinette; Debra L Breneman; T Funicella; R Kalb; J Moore
A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis.
Journal of the American Academy of Dermatology 1996;35(2 Pt 1):268-9.
1996: S Truter; J Rosenbaum-Fiedler; Allen N Sapadin; Mark Lebwohl
Calcification of elastic fibers in pseudoxanthoma elasticum.
The Mount Sinai journal of medicine, New York 1996;63(3-4):210-5.
1996: M S Green; J H Prystowsky; Steven R Cohen; J I Cohen; Mark Lebwohl
Infectious complications of erythrodermic psoriasis.
Journal of the American Academy of Dermatology 1996;34(5 Pt 2):911-4.
1996: Mark Lebwohl
Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema.
Cutis; cutaneous medicine for the practitioner 1996;57(2 Suppl):62-8.
1995: Mark Lebwohl
Future psoriasis therapy.
Dermatologic clinics 1995;13(4):915-23.
1995: Mark Lebwohl; E Abel; M Zanolli; J Koo; L Drake
Topical therapy for psoriasis.
International journal of dermatology 1995;34(10):673-84.
1995: Mark Lebwohl; M O Longas; J Konstadt; R Koreen; G A Grabowski; R Phelps; G Lemlich; E Schwartz
Hyaluronic acid and dermatan sulfate in non-lesional pseudoxanthoma elasticum skin.
Clinica chimica acta; international journal of clinical chemistry 1995;238(1):101-7.
1995: C M Gerardi; H Kahn; Mark Lebwohl
Case 2-1995. From the weekly grand rounds of the Department of Dermatology at the Mount Sinai Hospital.
The Mount Sinai journal of medicine, New York 1995;62(3):243-8.
1995: Mark Lebwohl; J Martinez; P Weber; R DeLuca
Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy.
Journal of the American Academy of Dermatology 1995;32(3):469-71.
1995: C Gerardi; Mark Lebwohl
Case 1-1994. From the Weekly Grand Rounds of the Department of Dermatology at the Mount Sinai Hospital.
The Mount Sinai journal of medicine, New York 1995;62(1):60-1.
1994: M G Lebwohl; E Schwartz; L Jacobs; Mark Lebwohl; Lynn Y Sakai; Raul Fleischmajer
Abnormalities of fibrillin in acquired cutis laxa.
Journal of the American Academy of Dermatology 1994;30(6):950-4.
1994: E J Fryer; Mark Lebwohl
Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis.
Journal of the American Academy of Dermatology 1994;30(4):651-3.
1994: Mark Lebwohl; K Neldner; F M Pope; A De Paepe; A M Christiano; C D Boyd; J Uitto; Victor A McKusick
Classification of pseudoxanthoma elasticum: report of a consensus conference.
Journal of the American Academy of Dermatology 1994;30(1):103-7.
1993: E Schwartz; F A Cruickshank; C C Christensen; JS Perlish; Mark Lebwohl
Collagen alterations in chronically sun-damaged human skin.
Photochemistry and photobiology 1993;58(6):841-4.
1993: B C Yen; H Kahn; A L Schiller; M J Klein; Robert G Phelps; Mark Lebwohl
Multiple hamartoma syndrome with osteosarcoma.
Archives of pathology & laboratory medicine 1993;117(12):1252-4.
1993: Mark Lebwohl; E Peets; V Chen
Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy.
International journal of dermatology 1993;32(11):830-1.
1993: Mark Lebwohl
Images in clinical medicine. Pseudoxanthoma elasticum.
The New England journal of medicine 1993;329(17):1240.
1993: Mark Lebwohl; J Halperin; Robert G Phelps
Brief report: occult pseudoxanthoma elasticum in patients with premature cardiovascular disease.
The New England journal of medicine 1993;329(17):1237-9.
1993: G Lemlich; M Green; R Phelps; Mark Lebwohl; Philip C Don; M Gordon
Cutaneous reactions to vitamin K1 injections.
Journal of the American Academy of Dermatology 1993;28(2 Pt 2):345-7.
1993: Mark Lebwohl; E Schwartz; G Lemlich; O Lovelace; F Shaikh-Bahai; Raul Fleischmajer
Abnormalities of connective tissue components in lesional and non-lesional tissue of patients with pseudoxanthoma elasticum.
Archives of dermatological research 1993;285(3):121-6.
1992: K Davis; E J Bottone; D Lucas; Mark Lebwohl
Sterility of refrigerated injectable collagen syringes after injection of patient.
Journal of the American Academy of Dermatology 1992;27(6 Pt 1):959-61.
1992: H W Bruckner; Mayer Gorbaty; R Lipsztein; G Kranjac; Mark Lebwohl
Treatment of a large high-grade neurofibrosarcoma with concomitant vinblastine, doxorubicin, and radiotherapy.
The Mount Sinai journal of medicine, New York 1992;59(5):429-32.
1992: M Keltz; Mark Lebwohl; S Bishop
Peristomal pyoderma gangrenosum.
Journal of the American Academy of Dermatology 1992;27(2 Pt 2):360-4.
1992: Mark Lebwohl
Differential diagnosis of pigmented lesions of the skin.
The Mount Sinai journal of medicine, New York 1992;59(3):194-7.
1991: E Schwartz; M Thieberg; F A Cruickshank; Mark Lebwohl
Elastase digestion of normal and pseudoxanthoma elasticum lesional skin elastins.
Experimental and molecular pathology 1991;55(2):190-5.
1991: Marsha L Gordon; Mark Lebwohl; Robert G Phelps; Steven R Cohen; Raul Fleischmajer
Eosinophilic fasciitis associated with tryptophan ingestion. A manifestation of eosinophilia-myalgia syndrome.
Archives of dermatology 1991;127(2):217-20.
1990: Mark Lebwohl; P Contard
Interferon and condylomata acuminata.
International journal of dermatology 1990;29(10):699-705.
1990: E Schwartz; F A Cruickshank; Mark Lebwohl
Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography.
Experimental and molecular pathology 1990;52(1):63-8.
1989: R D London; Mark Lebwohl
Acquired ichthyosis and hyperparathyroidism.
Journal of the American Academy of Dermatology 1989;21(4 Pt 1):801-2.
1988: E Schwartz; F A Cruickshank; Mark Lebwohl
Elastase-like protease and elastolytic activities expressed in cultured dermal fibroblasts derived from lesional skin of patients with pseudoxanthoma elasticum, actinic elastosis, and cutis laxa.
Clinica chimica acta; international journal of clinical chemistry 1988;176(2):219-24.
1987: G Lemlich; L Schwam; Mark Lebwohl
Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases.
Journal of the American Academy of Dermatology 1987;16(2 Pt 1):319-25.